European Society for Medical Oncology Congress
Cetuximab conferred benefits regardless of tumor HPV status
Among patients with recurrent or metastatic squamous cell carcinoma of the head and neck, the survival benefits conferred by the addition of cetuximab to cisplatin chemotherapy were independent of HPV status, according to results of a retrospective analysis.
Cetuximab conferred benefits regardless of tumor HPV status
Among patients with recurrent or metastatic squamous cell carcinoma of the head and neck, the survival benefits conferred by the addition of cetuximab to cisplatin chemotherapy were independent of HPV status, according to results of a retrospective analysis.
Chemoradiotherapy superior to panitumumab-radiotherapy combination
Chemoradiotherapy conferred better locoregional control rates than panitumumab plus radiotherapy in a cohort of patients with locally advanced squamous cell carcinoma of the head and neck, according to results of the CONCERT-2 study.
Targeted drugs for mRCC effective in first-line treatment
The oral, multi-kinase angiogenesis inhibitors pazopanib and sunitinib demonstrated similar effectiveness in controlling metastatic renal cell carcinoma, according to results of the COMPARZ trial.
Crizotinib superior to single-agent chemotherapy for ALK-positive advanced NSCLC
Crizotinib proved more effective than standard chemotherapy for patients with advanced, ALK-positive non–small-cell lung cancer, according to phase 3 study results presented at the 2012 Congress of the European Society for Medical Oncology in Vienna.
Longer trastuzumab treatment failed to improve outcomes in HER-2–positive breast cancer
Women with HER-2–positive breast cancer who underwent 2 years of treatment with trastuzumab received no additional benefit than women who underwent 1 year of treatment, according to study results presented at the 2012 Congress of the European Society for Medical Oncology in Vienna.
Gefitinib extended PFS in esophageal cancer
Gefitinib significantly improved quality of life and prolonged PFS for patients with metastatic esophageal cancer after chemotherapy, according to results of a phase 3 trial.
Sorafenib as salvage regimen failed to extend OS in NSCLC
Treatment with sorafenib as either third- or fourth-line therapy did not extend OS in patients with advanced non–small cell lung cancer, according to study results presented at the 2012 Congress of the European Society for Medical Oncology in Vienna.